AI-01 Kv1.3 expression on systemic lupus erythematosus (SLE) urinary leukocytes. (August 2018)

• Record Type: Journal Article
• Authors: Hinkle, Andrew; Yuasa, Megan; Peckham, David; Phillips, Craig; Iadonato, Shawn; Probst, Peter; Elkon, Keith; Stevens, Anne M
• Is Part Of: Lupus science & medicine. Volume 5(2018)Supplement 2
• Page Start: A1
• Page End: A1
• Publication Date: 2018-08
• Subjects: Systemic lupus erythematosus -- Periodicals; 616.772005
• DOI: 10.1136/lupus-2018-lsm.1
• Languages: English
• ISSNs: 2398-8851

Abstract

Abstract : Background: Effector memory T lymphocytes (TEM ) implicated in the immunopathogenesis of SLE have been detected in the urine of patients with lupus nephritis. As TEM depend on the voltage-gated potassium channel Kv1.3 for activation-induced calcium signalling, activated TEM represents a potential target for the novel Kv1.3 blockade therapy dalazatide. In active SLE nephritis, Kv1.3 is upregulated on peripheral blood CD8+ TEM and cytokine production was inhibited in SLE T lymphocytes. We therefore hypothesized that Kv1.3 is expressed on urinary leukocytes from patients with lupus nephritis. Methods: Urinary cells were isolated in 33 samples from patients with SLE ages 15–41 years, (mean 19, IQR 16.2–19.3). Immunofluorescence was performed to quantify and characterize cells expressing Kv1.3. Urinary leukocytes were defined as non-epithelioid cells by morphology. Leukocyte subsets were defined as CD3+ T lymphocytes, CD20+ B lymphocytes, or CD14+ macrophage. Results: In the urine, leukocytes expressing Kv1.3 were found in samples from every subject studied. Overall, Kv1.3 expression was detected on a mean of 3.5% of leukocytes (range 0.1%–13.4%; IQR 0.8%–5.1%) with higher levels in patients with active disease (4.8%, IQR 1%–6.7%) compared to patients with inactive disease (2.1%, IQR 0.8%–2.7%, p=0.04). CD3+ lymphocytes expressing Kv1.3 were found in all subjects (mean 52% of CD3+ cells, IQR 33%–100%). In 90% of subjects, Kv1.3 was detected on CD20+ B lymphocytes (mean 68%, IQR 46%–100%), and in 90% of subjects CD14+ macrophages (mean 69%, IQR 46%–100%). Patients with class III or IV nephritis had increased frequencies of leukocytes expressing Kv1.3 (6%) compared to patients with Class V nephritis (2%, p=0.01) or no nephritis (1.8%, p=0.01). Conclusions: Kv1.3 is detectable on SLE urinary B lymphocytes, T lymphocytes, and macrophage, implying that inflammatory cells in the kidney may be targeted by this channel. Peripheral blood cell expression and functional data suggest that SLE activated TEM lymphocytes may be susceptible to inhibition by dalazatide. Acknowledgements: This work was funded by Seattle Children's Research Institute and Kineta, Inc.